EGFR and non-small cell lung carcinoma: EGFR mAbs, including cetuximab, panitumumab, and necitumumab, have shown limited activity in NSCLC but have specific indications in the treatment of colorectal cancer and squamous cell carcinoma of the head and neck (44).